| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Neuroendocrine Unit (L.K., V.C.S., A.K.), Department of Neurology (P.N.R.), and the General Clinical Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114
Address all correspondence and requests for reprints to: Laurence Katznelson, M.D., Neuroendocrine Unit, Massachusetts General Hospital, 55 Fruit Street, BUL457B, Boston, Massachusetts 02114-2696. E-mail: katznelsonl{at}a1.mgh.harvard.edu
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
Development of normative data on PRL pulsations in postmenopausal women is important for understanding the role of estrogen in maintaining PRL secretion. For example, with the widespread use of estrogen agonists/antagonists, such as tamoxifen, the effect of estrogen on pituitary function needs to be defined further (6). Investigations into the effect of postmenopausal status on pulsatile secretion of PRL have been limited with regard to the use of pulse analysis or control groups (1, 5, 7).
To characterize the diurnal pulsatile secretion of PRL in postmenopausal women, it is also necessary to investigate PRL secretory dynamics in estrogen-sufficient subjects and men, a group with relative hypoestrogenemia. Therefore, we performed frequent sampling of PRL in postmenopausal women, cycling women, and men to determine 1) PRL pulsation patterns in postmenopausal women, and 2) the effect of gonadal status and gender on PRL pulsatile secretion.
| Subjects and Methods |
|---|
|
|
|---|
Thirty-seven subjects were studied. Seven postmenopausal women (mean age, 56 ± 4 yr; range, 5162 yr) were studied. Menopausal status was confirmed by elevated serum LH and FSH values (>25 mIU/mL) and undetectable serum estradiol levels. None of these women had previously received estrogen replacement. Eight normal men (mean age, 25 ± 8 yr; range, 2043 yr) were studied. All men had a history of normal sexual and reproductive function and had serum testosterone levels greater than 10.4 nmol/L on at least 2 readings. The mean serum testosterone value was 24.1 ± 8.6 nmol/L (range, 18.244.1 nmol/L). Twenty-two premenopausal women with a history of normal menstrual cycles (cycling women; age, 28 ± 5 yr; range, 1938 yr) were also studied. The age of menarche ranged from 1116 yr. None of the women had taken oral contraceptives for at least 1 yr before the study. Eight women were studied during the early follicular phase (days 17), 10 women were studied during the late follicular phase (days 813), and 8 women were studied during the luteal phase (days 2125). Three of these women were assessed during more than one phase of the menstrual cycle. Luteal phase was confirmed by a serum progesterone level greater than 16 nmol/L. The mean progesterone level in the luteal subjects was 61 ± 12 nmol/L.
All subjects had normal histories, physical examinations, and renal and thyroid function tests. The study was approved by the subcommittee on human studies at the Massachusetts General Hospital, and written informed consent was obtained from all subjects.
Experimental protocol
Subjects were admitted to the Clinical Research Center at Massachusetts General Hospital at 0800 h for placement of an iv catheter. Beginning at 0900 h, venous samples were obtained every 10 min for 24 h. Time of sleep was recorded after visual inspection by a research nurse. After completion of the 24-h sampling, subjects received TRH (200 µg, iv), and blood samples for PRL determination were obtained 0, 10, 20, 30, and 60 min after TRH administration. Serum samples were stored at -20 C and assayed in bulk at study completion.
All subjects were given a diet of 30% protein, 30% fat, and 40% carbohydrates during the admission. Meals were given at 0830, 1200, and 1800 h. Smoking and caffeine were not permitted. Subjects were allowed to ambulate ad libitum.
Hormone assays
Serum testosterone was measured by RIA (ICN Biomedical, Carson, CA). This assay has a detection limit of 0.3 nmol/L, and an intraassay coefficient of variation of 11%. Serum progesterone, PRL, LH, and FSH were determined by previously described methods (8). All PRL samples for an individual patient were determined in the same assay to avoid interassay variation.
Pulse detection
Pulses were detected by means of the Pulsar program, using a conservative assay coefficient of variation of 13% and cut-off criteria identical to those reported in a previous analysis of PRL pulsatility (9).
Statistics
Data were analyzed by a one- or two-way ANOVA, with repeated measures as appropriate. Multiple comparisons were performed using Scheffes test. PRL pulse analysis was performed over the 24-h period or during the day (08001950 h) vs. the night (20000750 h).
| Results |
|---|
|
|
|---|
|
|
|
|
|
|
|
| Discussion |
|---|
|
|
|---|
This is the first investigation that details PRL pulse characteristics in postmenopausal women and demonstrates differences in pulsatile secretion of PRL in the night compared to the day. In a previous study in five postmenopausal women, a circadian rhythm in PRL secretion was demonstrated after measurement of PRL at 1-h intervals (10). However, further analysis of pulse characteristics was not performed in their study. Previous studies of postmenopausal women have not included estrogen-sufficient cycling women or men for comparison. Our data serve as an important control database for further investigations regarding pathological states such as PRL-secreting pituitary tumors in postmenopausal women (6).
We found that postmenopausal women had different pulse characteristics, including lower pulse amplitude, frequency, and pulse duration during the day and night phases, compared to those in cycling women. One possible explanation for the difference between postmenopausal women and cycling women is an effect of estrogen on PRL secretion. Estradiol pulses precede PRL pulses by approximately 2 h, suggesting that rising levels of estradiol facilitate the secretion of PRL (4). Further evidence for a role of estrogen in regulating PRL secretion comes from studies involving the administration of estradiol to postmenopausal women (11). Chang et al. (10) performed hourly PRL sampling in five postmenopausal women before and after administration of 50 µg/day ethinyl estradiol for 4 weeks. In this study, estrogen administration resulted in an augmentation of PRL secretion in a diurnal rhythm. Therefore, although detailed pulse analysis was not performed, this study is consistent with a stimulatory effect of estrogen on the secretion of PRL. Veldhuis et al. (12) found that estrogen administration resulted in a significant increase in pulse amplitude without a change in pulse frequency in postmenopausal women. Consistent with these results, cycling women in our study had higher mean PRL levels and pulse amplitudes compared to postmenopausal women. These data support the hypothesis that estrogens play an important physiological role in modulating PRL secretion. In contrast to Veldhuis et al. (12), we also found group differences in PRL pulse frequency, suggesting altered hypothalamic regulation. Sleep quality, duration, and onset are determinants of PRL release, and, although a formal assessment of sleep cycles was not performed, it is possible that differences in sleep patterns may have contributed to the results in this study (1). In addition, age-related alterations in the regulation of PRL secretion may contribute to the observed group differences (7, 13).
Consistent with previous reports in men, we found that PRL was secreted in a pulsatile, diurnal pattern, with higher pulse amplitude and pulse frequency at night (14, 15). In contrast to a prior study in 12 young men, our data also suggest that PRL pulse frequency is higher at night (15). The reasons behind this difference are unclear.
Administration of TRH resulted in a greater absolute increment in PRL secretion in cycling women compared to men. There was a tendency for less TRH-induced PRL release in postmenopausal women compared to cycling women, but this difference was not significant. Although serum PRL levels are elevated in the setting of primary hypothyroidism (16), the role of TRH in the physiological regulation of PRL is unclear. Estrogens may augment the effect of hypothalamic peptides, such as TRH, on PRL secretion (17). In postmenopausal women, exogenous estrogens were shown in one study to enhance the PRL response to TRH (18), but not in another (19). Circulating estradiol levels may directly or via effects on hypothalamic factors modulate PRL pulsatility and contribute to the differences seen between genders and between postmenopausal and cycling women. Our data also suggest that there may be less PRL reserve in men and postmenopausal women than in cycling women.
We did not demonstrate a change in mean PRL levels across the menstrual cycle. Our data are consistent with those from previous studies (20, 21), but contrast with others that have shown an increase in PRL levels during the periovulatory and luteal phases of the menstrual cycle (22, 23). Differences between data from previous studies and the present results may be due to the fact that we performed PRL sampling more frequently than in other studies. However, our study may be limited by the fact that subjects were not studied prospectively across a menstrual cycle, and therefore, there may not have been sufficient power to demonstrate a significant change across the menstrual cycle. Nevertheless, it is unlikely that dramatic changes in PRL levels are present across the menstrual cycle.
We investigated PRL secretion in postmenopausal women and demonstrated the presence of a circadian rhythm in mean PRL levels, PRL pulse amplitude, and pulse frequency. These values were similar to those in younger men and lower than those in cycling, estrogen-sufficient women. These data suggest that estrogens play a critical role in the regulation of PRL in both women and men. Further studies are necessary to determine other mechanisms that underlie the differential regulation of PRL pulsatile secretion associated with gender and age.
| Footnotes |
|---|
Received September 16, 1997.
Revised December 2, 1997.
Accepted December 9, 1997.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
N. Kalleinen, P. Polo-Kantola, K. Irjala, T. Porkka-Heiskanen, T. Vahlberg, A. Virkki, and O. Polo 24-Hour Serum Levels of Growth Hormone, Prolactin, and Cortisol in Pre- and Postmenopausal Women: The Effect of Combined Estrogen and Progestin Treatment J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1655 - 1661. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Ben-Jonathan, C. R. LaPensee, and E. W. LaPensee What Can We Learn from Rodents about Prolactin in Humans? Endocr. Rev., February 1, 2008; 29(1): 1 - 41. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Saaresranta and O. Polo Hormones and Breathing Chest, December 1, 2002; 122(6): 2165 - 2182. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Landis, M. J. Lentz, J. Rothermel, S. C. Riffle, D. Chapman, D. Buchwald, and J. L. F. Shaver Decreased Nocturnal Levels of Prolactin and Growth Hormone in Women with Fibromyalgia J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1672 - 1678. [Abstract] [Full Text] |
||||
![]() |
F. C. Baker, H. S. Driver, G. G. Rogers, J. Paiker, and D. Mitchell High nocturnal body temperatures and disturbed sleep in women with primary dysmenorrhea Am J Physiol Endocrinol Metab, December 1, 1999; 277(6): E1013 - E1021. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |